Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA
Filed with ASX · · 3 pages · English
Sydney, Australia, 5 June 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce that the Phase 1B ADVENT-AML trial of CHM CORE-NK has advanced to the next planned cohort. The ADVENT-AML (NCT05834244) Phase 1B clinical trial is an investigator-initiated trial currently open to enrollment at The University of Texas MD Anderso
Chimeric Therapeutics Limited on 6ix
Story so far
Earlier from Chimeric Therapeutics
- Chimeric opens CHM CDH17 Phase 1/2 trial
- CHM CDH17 Phase 1/2 clinical trial approved for initiation
- Resignation of CEO and Managing Director
- Clinical milestones for 2024 & 2023 successes highlighted
- Half Yearly Report and Accounts
Later from Chimeric Therapeutics
- First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
- First patient dosed in Phase 1/2 trial of CHM CDH17
- Appendix 4E and Preliminary Final Report
- AML patient achieves Complete Response in CHM CORE-NK trial
- $5 million Placement to progress CHM CDH17 trial
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics